Compare Bank of New York Mellon Corp (BNY) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Philip Morris International Inc. — how do they compare? Bank of New York Mellon Corp trades at $153 (market cap $106.05B), while Philip Morris International Inc. trades at $176.61 (market cap $274.23B). The key difference: Philip Morris International Inc. is far larger — about 2.6× Bank of New York Mellon Corp's market cap, and Philip Morris International Inc. pays the higher dividend (3.34%). Which is the better fit depends on your goals.
| BNY | PM | |
|---|---|---|
Market Cap | $106.05B | $274.23B |
Sector | Financials | Consumer Staples |
52-Week High | $154.50 | $191.86 |
52-Week Low | $95.16 | $144.33 |
Dividend Yield | 1.37% | 3.34% |
Enterprise Value | — | $320.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY trades at $151.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue growth has been steady, rising from $16.0B in 2022 to $19.8B in 2025, while net income margin improved to 29.21%. Analyst consensus is mixed with 38% buy ratings but a $156 price target suggesting modest upside. Recent news highlights strong fee income expectations and a planned 19% dividend increase.
BNY demonstrates solid fundamental strength with improving profitability and consistent earnings beats. The stock offers potential upside to analyst targets and dividend growth, but faces risks from high investing cash outflows and competitive pressures. Current valuation metrics appear reasonable relative to historical performance, though investors should monitor Q2 earnings results for confirmation of growth trajectory.
Philip Morris International (PM) trades at $175.95, down 3.12% on the day, amid a recent profit forecast revision. The stock shows a bullish technical signal with key support at $175 and resistance at $183. Fundamentally, the company reported strong 2025 results with $40.65B revenue and $11.35B net income, though a $500M impairment charge and cost pressures prompted a lowered 2026 outlook. Analyst sentiment remains positive with a $194 consensus price target and 68% buy ratings.
The outlook is cautiously optimistic; earnings growth and the IQOS brand strength offer upside, but regulatory risks and illicit market pressures pose challenges. The current price presents a potential entry point below the analyst target, though investors must weigh margin pressures from energy costs and currency swings noted in recent company guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
